Overview

Efficacy and Safety Study of Ozanimod in Relapsing Multiple Sclerosis

Status:
Completed

Trial end date:
2017-04-13

Target enrollment:
0

Participant gender:
All

Summary

This study is a two-part trial consisting of Part A (see NCT01628393) and Part B, presented within this record. The primary objective of Part B is to assess whether the clinical efficacy of ozanimod (RPC1063) is superior to interferon beta-1a (IFN β-1a; Avonex®) in reducing the rate of clinical relapses at the end of Month 24 in patients with relapsing multiple sclerosis (RMS).

Phase:

Phase 3

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Celgene

Treatments:

Interferon beta-1a
Interferon-beta
Interferons
Ozanimod

Criteria

Inclusion Criteria:

- Multiple sclerosis as diagnosed by the revised 2010 McDonald criteria

- Expanded Disability Status Scale (EDSS) score between 0 and 5.0 at baseline

Exclusion Criteria:

- Primary progressive multiple sclerosis